Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 9/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17979731 | 1.00 | ATM (0.49) | ATMNUDT1HTR6ADORA2AADORA1 | |
| SCHEMBL17979733 | 1.00 | ATM (0.49) | ATMNUDT1HTR6ADORA2AADORA1 | |
| SCHEMBL17979742 | 0.97 | ATM (0.52) | ATMNUDT1HTR6 | |
| SCHEMBL17979751 | 0.97 | ATM (0.52) | ATMNUDT1HTR6 | |
| SCHEMBL17979766 | 0.97 | ATM (0.52) | ATMNUDT1HTR6 | |
| SCHEMBL17979677 | 0.87 | HRH4 (0.47) | ATMNUDT1HTR6ADORA2AADORA1 | |
| SCHEMBL17979673 | 0.86 | HRH4 (0.48) | ATMNUDT1HTR6ADORA2AADORA1 | |
| SCHEMBL17979778 | 0.83 | ATM (0.49) | ATMNUDT1HTR6 | |
| SCHEMBL18019761 | 0.80 | NUDT1 (0.52) | NUDT1ADORA2AADORA1 | |
| SCHEMBL18019759 | 0.80 | NUDT1 (0.52) | NUDT1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | ATM 1545/4885NUDT1 10/4885HTR6 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.